Companies / BOC Sciences / blinatumomab
BOC Sciences

blinatumomab | BOC Sciences

Blinatumomab is a monoclonal antibody used for the treatment of Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It effects against tumor cells via binding to a CD3 site for T cells and a CD19 site for the target B cells, which express both in pediatric and adult populations.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.